Cefmenoxime

As a third-generation semi-synthetic cephalosporin antibiotic, cefmenoxime exerts a bactericidal effect by inhibiting the biosynthesis of bacterial cell walls. It has broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria, and its efficacy against drug-resistant strains such as *Pseudomonas aeruginosa*, *Escherichia coli* and *Klebsiella pneumoniae* is superior to that of some previous generations of cephalosporin products. Clinically, it is mainly used to treat moderate to severe infections caused by sensitive bacteria, including respiratory system infections, urinary system infections, biliary tract infections, abdominal infections, obstetric and gynecological infections, and sepsis. It is applicable to adults and children without a history of cephalosporin allergy, and is one of the important options for clinical anti-infective treatment.

At present, the global market size of cefmenoxime is approximately USD 1.87 billion, with a compound annual growth rate maintained at around 4.2%. The growth momentum mainly comes from the continuous release of demand for anti-infective drugs in low- and middle-income countries. In terms of the domestic market, the annual sales of cefmenoxime preparations exceed RMB 2 billion, of which generic drugs account for 94%, indicating relatively sufficient market competition. On the API side, China's production capacity accounts for 72% of the global total production capacity, making China a major exporter of cefmenoxime.

The original developer of cefmenoxime is Takeda Pharmaceutical Company Limited of Japan, with the original brand name "Bestcall". Its core compound patent expired in 2009 in Japan and major European and American markets, and the compound patent in China also terminated in 2009. The main dosage form approved for the original drug is cefmenoxime hydrochloride for injection, available in two specifications of 0.5g and 1.0g. It has been included in the China Listed Drug Catalogue as a reference listed drug. At present, 16 cefmenoxime hydrochloride APIs in China have obtained CDE registration numbers (status A), and another 27 enterprises have obtained approval for the marketing of cefmenoxime for injection preparations. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of cefmenoxime impurity reference standards. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can provide stable impurity reference standard support for API manufacturers, preparation R&D institutions and drug inspection units, facilitating the advancement of the entire process of product R&D and quality control.